You just read:

Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin mesylate)

News provided by

Eisai Inc.

May 13, 2020, 19:44 ET